Lyon, France, June 30th, 2016. Alaxia SAS announced today an agreement with Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), Bethesda, Md., to help support the first-in-patient clinical study of its inhaled antimicrobial drug candidate ALX-009.
By delivering two key endogenous antimicrobial substances directly to the lung, ALX-009 is intended to compensate for the defective innate lung defense system of people with cystic fibrosis (CF). ALX-009 already demonstrated in vitro its therapeutic potential against a wide range of bacterial species infecting CF lungs and particularly against clinical isolates with natural or acquired multi-drug resistance. ALX-009 efficacy is not altered by complex structures such as biofilm or sputum present in CF lungs. ALX-009 has the potential to limit emergence of resistance and induction of cross-resistance to available antibiotics thanks to its innovative mode of action. A Phase I clinical trial involving healthy volunteers and CF patients is ongoing.
CFFT, the nonprofit drug discovery and development arm of the Cystic Fibrosis Foundation, committed $1.7 million to Alaxia to expedite the development of ALX-009 for cystic fibrosis patients.
Pascale Gaillard, General Manager of Alaxia, commented on the award: “We are honored and delighted that Cystic Fibrosis Foundation Therapeutics recognizes the unique therapeutic potential of our drug candidate by supporting the development of ALX-009. This CFFT award enables us to accelerate the clinical development of ALX-009, and we really appreciate working with CFFT on the remaining clinical development path in bringing this new drug to people with cystic fibrosis.”
About Cystic Fibrosis:
Cystic fibrosis (CF) is a life-threatening disease that affects the lungs and digestive system and impacts about 70,000 people worldwide. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene which results in either no CFTR protein or an abnormal CFTR protein that does not function properly. This dysfunctional protein causes the body to accumulate excessive levels of unusually thick mucus in the lungs. This excessive sticky mucus becomes a site for recurrent infections that can require hospitalization. Respiratory distress in CF — defined as acute difficulty in breathing, infection and/or hospitalization — is most commonly related to mucus accumulation and lung infections that result in damage to lung tissue.
For more information on CF, please visit www.cff.org
About Alaxia SAS:
Alaxia SAS is a French clinical stage biotech company affiliated to Stragen Pharma and supported by BPI France. For additional info, please, visit www.alaxia-pharma.eu
Alaxia’s aim is to address unmet medical needs, fighting infections through its innovative Hypothiocyanite/Lactoferrin technology, by developing products and therapies to market or license to suitable partners.
Contact: Philippe Bordeau, VP Innovation, +33 437 532 637, email@example.com
The CFFT press release can be found here: CFF Press Release